We then evaluated NK92 cell cytotoxicity against K562 chronic myeloid leukemia cells and THP-1 acute monocytic leukemia cells, given their expression of B7-H6, a ligand for NKp30 (41, 42), and NKp30 as a prognostic biomarker in AML (26, 43, 44). This evidence concerns the gene NCR3 and chronic myelogenous leukemia, BCR-ABL1 positive.